A Phase 1b/3 Global, Randomized, Double-blind, Placebo Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Tazemetostat in Combination With Doxorubicin as Therapy for Advanced Epithelioid Sarcoma
Sponsor: Epizyme, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS7479
U.S. Govt. ID: NCT04204941
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to learn about the effects, safety, and proper dosage of tazemetostat in combination with doxorubicin for the treatment of soft tissue sarcoma. Doxorubicin is a common therapy for soft tissue sarcoma, but is not FDA approved in combination with tazemetostat. This study treatment combination may suppress or prevent tumor growth by inhibiting certain enzymes.
This study is closed
Investigator
Matthew Ingham, MD
Do You Qualify?
Are you aged 18 years or older? Yes No
Do you have confirmed diagnosis of soft tissue sarcoma? Yes No
Have you ever taken tazemetostat or other systemic cancer treatments? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE